← All trials
NCT06663631
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Nov 30, 2024
- Primary completion
- Jan 31, 2025
- Completion date
- Feb 28, 2025
- First posted
- Oct 29, 2024
- Last posted
- Nov 1, 2024
- Enrollment
- 32
- Arms / groups
- 5 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Capital Medical UniversityLead sponsor
- Capital Medical UniversityOfficial
- Capital Medical UniversitySponsor investigator
- Linyi People's HospitalCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.